Immunic (IMUX)

Executive Summary

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. More Details

Snowflake Analysis

Excellent balance sheet and overvalued.

Search for a company to compare.